Xyphos is led by two of the company’s principal co-founders, both with decades of experience in the research, development and commercialization of biotech-based human therapeutics within the biotechnology and pharmaceutical industries and leading research institutions.
James L. Knighton
MBA, Wharton School of Business, MS. Genetics, University of Pennsylvania; R&D, marketing and finance at the following companies: DuPont/DuPont Merck (1985-1994), Chiron (1994-1998), Sugen – CFO (1998-1999) and Caliper Life Sciences, President (1999-2004).
Kyle Landgraf, Ph.D.
Founding co-developer of the MicAbody™ and ConvertibleCAR™ platform technologies. Post doctoral fellow at Genentech. Education: University of Arizona (BS – Biochemistry) & University of Colorado (Ph.D.)
David W. Martin, MD
Duke Medical School; Professor of Medicine and Biochemistry, UCSF and Investigator, Howard Hughes Medical Institute; SVP of R&D at Genentech (1982-1990); Executive VP of R&D at DuPont Merck (1991-1993); President, Chiron Therapeutics (1994-1995) and founder and CEO of Eos Biotechnology (1997-2003).